8:55 am Chair’s Opening Remarks
Exploring Novel Conjugation Technologies to Widen the Possibilities for Early Design & Discovery
9:00 am Filtering Out Which Conjugation Technology to Use to Enhance Your ADCs Efficacy
Synopsis
- Evaluating which novel conjugation technology is the simplest and easiest to use
- Overviewing the novel conjugation technology landscape
- Comparing novel conjugation technologies to traditional ones
9:30 am Conjugation Technology-Enabled Solutions Broaden the Scope of Conjugatable Drugs
Synopsis
- Understanding how P5-labeling enables a rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
- Broadening the scope of drugs available for conjugation through novel Alco5-technology
- Outlining a superior linker-payload platform for the efficient and steady delivery of various drugs with different modes of actions
10:00 am Morning Networking Break
11:00 am Next-Generation Hydrophilic Click-Chemistry – Veraxa’s Selectable Site-Specific Bioconjugation
Synopsis
- Discussing the creation of selectable site-specific ADCs via incorporation of clickable non-canonical amino acids
- Overviewing the development of Veraxa’s hydrophilic click chemistry for bioconjugation
- Sharing Veraxa’s hydrophilic payload platform
11:30 am Harnessing Hinge-Region Disulfides for Homogenous DAR
Synopsis
- Outlining site-specific conjugation using hinge-region disulfides
- Developing a novel technology for homogenous DAR1
- Assessing the application to multiple ADCs and next-generation conjugates
12:00 pm Expanded Genetic Code Platform-Enabled Site-Specific Stable Linker-Payload Conjugation
Synopsis
- Expanded genetic code technology, recently covered in Nature, allows for site-specific conjugation and produces highly stable and homogenous ADCs
- The technology creates engineered proteins by site-specifically incorporating synthetic amino acids, precise modification and orthogonal chemistry for stable conjugation, and novel drug design with a potential wider therapeutic index
- Ambrx Biopharma has been developing expanded genetic code technology for over 20 years and is studying its potential to improve safety and efficacy of ADC technology in clinical trials, with lead assets ARX788 and ARX517, being studied in a Phase 2 clinical trail in HER2+ metastatic breast cancer patients, and a phase 1 study in metstatic castration resistant prostate cancer patients, respectively.
12:30 pm Networking Lunch
1:30 pm Highlighting How the Mode of Conjugation Impacts Challenges During Bioconjugation & Resulting ADC Behavior
Synopsis
- Honing conjugation chemistries concerning the mAb to develop and advance conjugation technologies
- Understanding the relationship between ADC design and thermal and chemical/ metabolic stability
- Analyzing how to align linker and conjugation chemistries with each payload property
2:00 pm Roundtable Discussion: Assessing the Development of New Site-Specific Conjugation Platforms
Synopsis
- Develop new conjugation platform for the generation of site-specific ADCs
2:30 pm Analyzing the Impact of Linker-Payload Technologies on Early-Phase Development
Synopsis
- Understanding the impact of linker payload properties on ADC properties and linker payload and ADC manufacturing processes across development stages
- Discussing the impact of linker payloads on analytical profile and analytical development
- Reviewing the criticality of ADC properties and quality attributes for in vivo outcomes
3:00 pm All Roads Lead To Rome: Diverse Approaches for Antibody-Drug Conjugates (ADCs)
Synopsis
- Learn about a new site-specific conjugation method for antibodies that retains the core glycan structure
- Engage in direct comparison of site-specific and non-specific conjugates
- Explore photo-cleavable linkers for spatial and temporal activation